T2 Biosystems Inc TTOO

Healthcare Biotechnology

T2 Biosystems, Inc. is an in vitro diagnostics company focused on the detection of sepsis-causing pathogens and antibiotic resistance genes. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The Company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. It also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.

NDAQ:TTOO - Post by User

T2 Biosystems Inc > TTOO.... Of course this rallies on last weeks NR

<< Previous

Bullboard Posts

Next >>

Post by Iseneschalon Jul 10, 2023 10:49am

33 Views

Post# 35533531

TTOO.... Of course this rallies on last weeks NR

T2 Biosystems Announces Conversion of Approximately Twenty Percent of CRG Term Loan into Equity

2023-07-06 05:00 ET - News Release

LEXINGTON, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the conversion of approximately 20% of its term loan with entities affiliated with CRG Servicing LLC (“CRG”) into T2 Biosystems common stock and Series B convertible preferred stock.

<< Previous

Bullboard Posts

Next >>

Fortune Minerals receives funding for NICO project development